PresentationGood morning, and welcome to Enanta Pharmaceuticals Conference Call. [Operator Instructions] Please be advised that this call is being recorded. I would now like to turn the call over to Jennifer Viera, Head of Investor Relations. Please go ahead.Jennifer VieraExecutive Director of Investor Relations & Corporate Communications Thank you, operator, and thanks to everyone for joining us this morning. The news release announcing the top line results of our RSVHR study became available earlier this ...

业绩总结 - 2025财年贡献利润为425万美元，较2024财年的亏损98万美元显著改善[8] - 2025财年收入为911万美元，较2024财年的990万美元下降8%[19] - 运营亏损从2024财年的3167万美元改善至2025财年的1040万美元，改善幅度为67%[19] - 调整后EBITDA从2024财年的1785万美元改善至2025财年的991万美元，改善幅度为44%[19] - 每个预订的贡献利润为9.96美元，较2024财年的-2.52美元显著改善[27] - 2025财年贡献利润占收入的47%[25] 用户数据 - 2025财年总预订量为426,788，较2024财年的387,821增长10%[19] - 重复用户比例从2024财年的7%提升至2025财年的13%[10] - 高质量主机（评分4.5及以上）占比从2024财年的31%提升至2025财年的49%[9] 融资与支出 - 2025财年总融资额为1650万美元，主要用于偿还债务和支持增长[16]